Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
45
KALV Quote, Financials, Valuation and Earnings
Last price:
$15.81
Seasonality move
:
-3.39%
Day range:
$15.58 - $16.11
52-week range:
$9.24 - $19.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
54.92x
P/B ratio:
47.07x
Volume:
352.5K
Avg. volume:
1.1M
1-year change:
48.78%
Market cap:
$800.1M
Revenue:
--
EPS (TTM):
-$4.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KALV
KalVista Pharmaceuticals, Inc.
|
$32.3M | -$0.53 | -- | -54.03% | $34.00 |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
$151.3M | $0.07 | 4.53% | 109900% | $21.20 |
|
BSEM
BioStem Technologies, Inc.
|
$55.2M | $0.02 | -37.86% | -100% | $25.5000 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$81M | -$0.18 | 63.91% | -57.98% | $9.11 |
|
MODD
Modular Medical, Inc.
|
-- | -$0.12 | -- | -47.83% | $8.00 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KALV
KalVista Pharmaceuticals, Inc.
|
$15.83 | $34.00 | $800.1M | -- | $0.00 | 0% | 54.92x |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
$7.45 | $21.20 | $1.8B | -- | $0.00 | 0% | 2.68x |
|
BSEM
BioStem Technologies, Inc.
|
$6.0540 | $25.5000 | $101.5M | 7.11x | $0.00 | 0% | 0.57x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.87 | $9.11 | $1.1B | -- | $0.00 | 0% | 3.80x |
|
MODD
Modular Medical, Inc.
|
$0.49 | $8.00 | $37.3M | -- | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.28 | $5.50 | $37.8M | -- | $0.00 | 0% | 4.41x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KALV
KalVista Pharmaceuticals, Inc.
|
94.33% | -2.502 | 45.9% | 6.99x |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
231.39% | 0.299 | 42.75% | 1.60x |
|
BSEM
BioStem Technologies, Inc.
|
6.34% | 0.058 | 4.31% | 3.87x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.707 | 6.28% | 2.92x |
|
MODD
Modular Medical, Inc.
|
7.89% | -2.408 | 1.82% | 1.35x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KALV
KalVista Pharmaceuticals, Inc.
|
$12.5M | -$46.1M | -97.51% | -243.25% | -336.33% | -$54.8M |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
$156.9M | $29.6M | -2.54% | -- | 18.57% | $39.8M |
|
BSEM
BioStem Technologies, Inc.
|
$9.2M | $1.4M | 44.01% | 48.25% | 13.83% | -- |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
MODD
Modular Medical, Inc.
|
-$430K | -$7.2M | -233.3% | -248.73% | -- | -$8.4M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
KalVista Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns KALV or BCRX?
BioCryst Pharmaceuticals, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of 8.09%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat BioCryst Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M BCRXBioCryst Pharmaceuticals, Inc.98.42% $0.06 $295.2M -
What do Analysts Say About KALV or BCRX?
KalVista Pharmaceuticals, Inc. has a consensus price target of $34.00, signalling upside risk potential of 114.78%. On the other hand BioCryst Pharmaceuticals, Inc. has an analysts' consensus of $21.20 which suggests that it could grow by 184.56%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than KalVista Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALVKalVista Pharmaceuticals, Inc.7 0 0 BCRXBioCryst Pharmaceuticals, Inc.7 0 0 -
Is KALV or BCRX More Risky?
KalVista Pharmaceuticals, Inc. has a beta of -0.191, which suggesting that the stock is 119.067% less volatile than S&P 500. In comparison BioCryst Pharmaceuticals, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.851%.
-
Which is a Better Dividend Stock KALV or BCRX?
KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioCryst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BioCryst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALV or BCRX?
KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are smaller than BioCryst Pharmaceuticals, Inc. quarterly revenues of $159.4M. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than BioCryst Pharmaceuticals, Inc.'s net income of $12.9M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while BioCryst Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 54.92x versus 2.68x for BioCryst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALVKalVista Pharmaceuticals, Inc.54.92x -- $13.7M -$49.5M BCRXBioCryst Pharmaceuticals, Inc.2.68x -- $159.4M $12.9M
-
Which has Higher Returns KALV or BSEM?
BioStem Technologies, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of 7.27%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat BioStem Technologies, Inc.'s return on equity of 48.25%.
Company Gross Margin Earnings Per Share Invested Capital KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M BSEMBioStem Technologies, Inc.87.95% $0.03 $53.4M -
What do Analysts Say About KALV or BSEM?
KalVista Pharmaceuticals, Inc. has a consensus price target of $34.00, signalling upside risk potential of 114.78%. On the other hand BioStem Technologies, Inc. has an analysts' consensus of $25.5000 which suggests that it could grow by 321.21%. Given that BioStem Technologies, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe BioStem Technologies, Inc. is more attractive than KalVista Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALVKalVista Pharmaceuticals, Inc.7 0 0 BSEMBioStem Technologies, Inc.0 0 0 -
Is KALV or BSEM More Risky?
KalVista Pharmaceuticals, Inc. has a beta of -0.191, which suggesting that the stock is 119.067% less volatile than S&P 500. In comparison BioStem Technologies, Inc. has a beta of -0.090, suggesting its less volatile than the S&P 500 by 108.955%.
-
Which is a Better Dividend Stock KALV or BSEM?
KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioStem Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BioStem Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALV or BSEM?
KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are larger than BioStem Technologies, Inc. quarterly revenues of $10.5M. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than BioStem Technologies, Inc.'s net income of $761.1K. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while BioStem Technologies, Inc.'s PE ratio is 7.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 54.92x versus 0.57x for BioStem Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALVKalVista Pharmaceuticals, Inc.54.92x -- $13.7M -$49.5M BSEMBioStem Technologies, Inc.0.57x 7.11x $10.5M $761.1K
-
Which has Higher Returns KALV or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of -135.28%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.
Company Gross Margin Earnings Per Share Invested Capital KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M -
What do Analysts Say About KALV or IOVA?
KalVista Pharmaceuticals, Inc. has a consensus price target of $34.00, signalling upside risk potential of 114.78%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $9.11 which suggests that it could grow by 217.46%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than KalVista Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALVKalVista Pharmaceuticals, Inc.7 0 0 IOVAIovance Biotherapeutics, Inc.6 4 0 -
Is KALV or IOVA More Risky?
KalVista Pharmaceuticals, Inc. has a beta of -0.191, which suggesting that the stock is 119.067% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.531%.
-
Which is a Better Dividend Stock KALV or IOVA?
KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALV or IOVA?
KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 54.92x versus 3.80x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALVKalVista Pharmaceuticals, Inc.54.92x -- $13.7M -$49.5M IOVAIovance Biotherapeutics, Inc.3.80x -- $67.5M -$91.3M
-
Which has Higher Returns KALV or MODD?
Modular Medical, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of --. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Modular Medical, Inc.'s return on equity of -248.73%.
Company Gross Margin Earnings Per Share Invested Capital KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M MODDModular Medical, Inc.-- -$0.11 $6.4M -
What do Analysts Say About KALV or MODD?
KalVista Pharmaceuticals, Inc. has a consensus price target of $34.00, signalling upside risk potential of 114.78%. On the other hand Modular Medical, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1525.36%. Given that Modular Medical, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe Modular Medical, Inc. is more attractive than KalVista Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALVKalVista Pharmaceuticals, Inc.7 0 0 MODDModular Medical, Inc.1 0 0 -
Is KALV or MODD More Risky?
KalVista Pharmaceuticals, Inc. has a beta of -0.191, which suggesting that the stock is 119.067% less volatile than S&P 500. In comparison Modular Medical, Inc. has a beta of -0.166, suggesting its less volatile than the S&P 500 by 116.615%.
-
Which is a Better Dividend Stock KALV or MODD?
KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Modular Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Modular Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALV or MODD?
KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are larger than Modular Medical, Inc. quarterly revenues of --. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than Modular Medical, Inc.'s net income of -$7.4M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Modular Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 54.92x versus -- for Modular Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALVKalVista Pharmaceuticals, Inc.54.92x -- $13.7M -$49.5M MODDModular Medical, Inc.-- -- -- -$7.4M
-
Which has Higher Returns KALV or PSTV?
Plus Therapeutics, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of -316.61%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About KALV or PSTV?
KalVista Pharmaceuticals, Inc. has a consensus price target of $34.00, signalling upside risk potential of 114.78%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1900%. Given that Plus Therapeutics, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than KalVista Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KALVKalVista Pharmaceuticals, Inc.7 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is KALV or PSTV More Risky?
KalVista Pharmaceuticals, Inc. has a beta of -0.191, which suggesting that the stock is 119.067% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock KALV or PSTV?
KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KALV or PSTV?
KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 54.92x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KALVKalVista Pharmaceuticals, Inc.54.92x -- $13.7M -$49.5M PSTVPlus Therapeutics, Inc.4.41x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 23
RingCentral, Inc. [RNG] is down 8.66% over the past day.
Sell
9
FROG alert for Feb 23
JFrog Ltd. [FROG] is down 2.94% over the past day.
Buy
72
SNSE alert for Feb 23
Sensei Biotherapeutics, Inc. [SNSE] is down 5.19% over the past day.
